72 related articles for article (PubMed ID: 10837621)
21. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
22. Regulation of helper T cell responses to staphylococcal superantigens.
Cameron SB; Nawijn MC; Kum WW; Savelkoul HF; Chow AW
Eur Cytokine Netw; 2001; 12(2):210-22. PubMed ID: 11399508
[TBL] [Abstract][Full Text] [Related]
23. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
24. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
[TBL] [Abstract][Full Text] [Related]
25. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1.
Buonpane RA; Moza B; Sundberg EJ; Kranz DM
J Mol Biol; 2005 Oct; 353(2):308-21. PubMed ID: 16171815
[TBL] [Abstract][Full Text] [Related]
26. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
27. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
28. High affinity T cell receptors from yeast display libraries block T cell activation by superantigens.
Kieke MC; Sundberg E; Shusta EV; Mariuzza RA; Wittrup KD; Kranz DM
J Mol Biol; 2001 Apr; 307(5):1305-15. PubMed ID: 11292343
[TBL] [Abstract][Full Text] [Related]
29. A new screening model for safety evaluation of superantigen-antibody recombinant fusion proteins (mAb Fab-SEA/E) using telemetric monitoring in conscious rabbits.
Ilbäck NG; Persson R; Gunnarsson K; Stålhandske T
J Pharmacol Toxicol Methods; 2002; 48(1):31-9. PubMed ID: 12750039
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
31. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
Brogan PA; Shah V; Klein N; Dillon MJ
Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503
[TBL] [Abstract][Full Text] [Related]
32. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
[TBL] [Abstract][Full Text] [Related]
33. Superantigen presentation by human retinal pigment epithelial cells to T cells is dependent on CD2-CD58 and CD18-CD54 molecule interactions.
Jørgensen A; Junker N; Kaestel CG; Liang Y; Wiencke A; la Cour M; Lui GM; Ødum N; Nissen MH; Röpke C
Exp Eye Res; 2001 Nov; 73(5):723-33. PubMed ID: 11747372
[TBL] [Abstract][Full Text] [Related]
34. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF
Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254
[TBL] [Abstract][Full Text] [Related]
35. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
36. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor.
Peng KW; Holler PD; Orr BA; Kranz DM; Russell SJ
Gene Ther; 2004 Aug; 11(15):1234-9. PubMed ID: 15215883
[TBL] [Abstract][Full Text] [Related]
37. The TCR Vbeta signature of bacterial superantigens spreads with stimulus strength.
Llewelyn M; Sriskandan S; Terrazzini N; Cohen J; Altmann DM
Int Immunol; 2006 Oct; 18(10):1433-41. PubMed ID: 16893924
[TBL] [Abstract][Full Text] [Related]
38. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
39. MHC class II-mediated antigen presentation by alloreactive rat CD4+ T cells does not induce regulatory properties.
Otto C; Heeg A; Kottenmeier S; Tiurbe GC; Thiede A; Ulrichs K
Transplant Proc; 2006 Apr; 38(3):755-6. PubMed ID: 16647463
[TBL] [Abstract][Full Text] [Related]
40. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
